CI
SBBP

Cigna Investments’s Strongbridge Biopharma plc. SBBP Stock Holding History

Cigna Investments’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,237
Closed -$103K – 788
2020
Q2 		$103K Buy
+27,237
New +$81.6K 0.01% 735

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cigna Investments's SBBP Position: Q3 2020 in Review

Cigna Investments sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2020, closing a stake of 27,237 shares — an estimated $103K sold.

Cigna Investments first reported a position in SBBP in Q2 2020 and held it in 1 quarter. The position peaked at $103K in Q2 2020. 77 funds tracked by Wall St. Rank hold SBBP as of Q3 2020.

  • Cigna Investments reported no remaining Strongbridge Biopharma plc. position as of Q3 2020 after selling out during the quarter.
  • Cigna Investments sold 27,237 Strongbridge Biopharma plc. shares in Q3 2020, an estimated $103K.
  • Cigna Investments first reported a position in Strongbridge Biopharma plc. in Q2 2020 and held it in 1 quarter.
  • Cigna Investments's Strongbridge Biopharma plc. position peaked at $103K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2020.

Based on Cigna Investments's 13F filing for Q3 2020, filed 12 Nov 2020.